Journal of Chemotherapy最新文献_第2页

Reevaluating immunotherapy's potential in first-line metastatic urothelial carcinoma. 重新评估免疫疗法在一线转移性尿路上皮癌中的潜力。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-09-01 Epub Date: 2024-08-06 DOI: 10.1080/1120009X.2024.2388475

Celia Castaño-Amores, Pelayo Nieto-Gómez

引用次数: 0

Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel. 白蛋白结合紫杉醇致急性重型至超重型周围神经病变的影响因素。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-08-19 DOI: 10.1080/1120009X.2025.2547144

Yi Huang, Lijuan Feng, Jing Hu, Fan Zeng

{"title":"Influencing factors of acute severe to very severe peripheral neuropathy induced by albumin-bound paclitaxel.","authors":"Yi Huang, Lijuan Feng, Jing Hu, Fan Zeng","doi":"10.1080/1120009X.2025.2547144","DOIUrl":"10.1080/1120009X.2025.2547144","url":null,"abstract":"Paclitaxel is the primary chemotherapy agents for many high-incidence cancers, and they also pose a significant risk for peripheral neuropathy. This study investigated the factors influencing paclitaxel-induced peripheral neuropathy (PIPN). We utilized PRO-CTCAE to assess the incidence of PIPN in patients receiving a tri-weekly regimen of single-agent albumin-bound paclitaxel through an online platform within one week after chemotherapy. Multivariable logistic regression was employed to analyze the impact of personal characteristics, clinical data and chemotherapy dose. All the statistical analyses were conducted in R studio. The incidence of acute severe to very severe PIPN was 36.7%, and the risk factors included per 200 mg increment in cumulative dose (OR 1.13, 95% 1.03 ∼ 1.24), estimated glomerular filtration rate < 90 ml/min/1.73m2 (OR 1.72, 95%CI 1.11 ∼ 2.66), anemia (OR 2.60, 95%CI 1.63 ∼ 4.15), albumin ≥ 40g/L (OR 1.74, 95%CI 1.04 ∼ 2.90), female (OR 1.98, 95%CI 1.19 ∼ 3.29), and overweight (OR 1.74, 95%CI 1.04 ∼ 2.91). The incidence of acute severe to very severe peripheral neuropathy caused by albumin-bound paclitaxel is relatively high. Nutritional status, gender, renal function and cumulative dose were all closely related to this incidence rate. Therefore, in the future, it is of great importance that a comprehensive and systematic assessment regarding the individual risks for patients be carried out in a meticulous manner. Relevant research should be conducted into the mechanisms underlying peripheral neuropathy, with particular attention to the role of individual factors.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bacteriophage therapy in clinical practice: case studies of Pseudomonas aeruginosa infections. 噬菌体治疗在临床中的应用：铜绿假单胞菌感染病例研究。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-08-14 DOI: 10.1080/1120009X.2025.2547147

Ahmed Elfadadny, Rokaia F Ragab, Osama Aldesoky Abd Alaziz, Habiba Y Essa, Esraa M Eltony, Mohamed M Ammar, Wedad M Nageeb

引用次数: 0

Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting. 艾力布林在转移性乳腺癌的现实世界-在印度设置前进的道路。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-08-07 DOI: 10.1080/1120009X.2025.2543127

Dinesh Chandra Doval, Rupal Tripathi, Shweta Jain, Pankaj Goyal, Chaturbhuj Agrawal, Sumit Goyal, Vineet Talwar, Ullas Batra, Rajeev Kumar, Ajay Kumar Dewan

{"title":"Eribulin in metastatic breast cancer in the real-world - the way forward in the Indian setting.","authors":"Dinesh Chandra Doval, Rupal Tripathi, Shweta Jain, Pankaj Goyal, Chaturbhuj Agrawal, Sumit Goyal, Vineet Talwar, Ullas Batra, Rajeev Kumar, Ajay Kumar Dewan","doi":"10.1080/1120009X.2025.2543127","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2543127","url":null,"abstract":"In a real-world setting, this study evaluated clinical parameters and outcomes with the administration of eribulin in heavily pre-treated Indian metastatic breast cancer (MBC) patients using electronic medical records. Among 145 patients, 46.2% were oestrogen/progesterone receptor-positive, 15.9% had HER2-overexpression, and 46.2% had triple-negative breast cancer (TNBC). Eribulin was administered as a 2nd, 3rd, 4th, and ≥5th line chemotherapy in 11.7%, 18.6%, 30.3%, and 39.3% patients, respectively. Grade ≥3 neutropenia occurred in 26.2% of patients. After six cycles, 1.8% had complete response, 17.5% partial response, 17.5% stable disease, and 57.9% experienced disease progression. The overall response rate was 7.6%. Median progression-free survival and overall survival were 3.9 and 11.6 months, respectively. Overall, the study shows low response rate with manageable toxicity. The findings highlight the need for further focused studies comparing eribulin with existing chemotherapies, especially in the Indian patients with disease heterogeneity and unique genetic makeup.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease. 西妥昔单抗治疗难治性特发性多中心Castleman病（类似igg4相关疾病）的惊人疗效

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-08-05 DOI: 10.1080/1120009X.2025.2542615

Xing Gong, Weiwei Yan, Feng Zhang, Dongdong Zhang

{"title":"Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease.","authors":"Xing Gong, Weiwei Yan, Feng Zhang, Dongdong Zhang","doi":"10.1080/1120009X.2025.2542615","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2542615","url":null,"abstract":"Castleman disease (CD) and immunoglobulin G4-related disease (IgG4-RD) are rare systemic immune-mediated disorders that share similar clinical manifestations and overlapping pathological features. We present a case of insidious idiopathic multicentric CD (iMCD) with elevated serum IgG4 levels, characterized by a persistent dry cough and widespread lymphadenopathy. A 38-year-old male patient exhibited persistent dry cough, generalized lymphadenopathy, and fatigue. An inguinal lymph node biopsy showed plasma cell-type MCD characteristics, such as atrophic lymphoid follicles and significant plasma cell infiltration. Immunohistochemical staining revealed positivity for IgG, CD38, and CD138, with over 50 IgG4-positive plasma cells per high-power field and an IgG4/IgG ratio of 40%, confirming the diagnosis of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of multicentric Castleman disease (iMCD-IPL). After receiving a siltuximab-based regimen followed by radiotherapy, the patient achieved a notable partial remission. We present a case illustrating the significant efficacy of siltuximab-based therapy in iMCD-IPL, resembling IgG4-related disease.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of ICIs-associated arthritis caused by Toripalimab initially presenting as oedema in both lower limbs. 多利帕利单抗引起的icis相关性关节炎1例，最初表现为双下肢水肿。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-08-04 DOI: 10.1080/1120009X.2025.2540173

Jie-Ling Zhang, Hao Yang, Zhi-Li Zhou, Jun-Jun Shen

引用次数: 0

Postmarket review of photosensitivity associated with select BRAF and MEK inhibitors. 与BRAF和MEK抑制剂相关的光敏性上市后评价。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-08-01 DOI: 10.1080/1120009X.2025.2539565

Nicholas Chow, Melissa Reyes, Afrouz Nayernama, Graça M Dores, Ida-Lina Diak

引用次数: 0

Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation. 早期达拉图单抗为基础的治疗在复发和难治性多发性骨髓瘤患者中显示出显著的有效性：一项真实世界的回顾性调查。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-07-29 DOI: 10.1080/1120009X.2025.2540172

Yi Chen, Qinyun Cai, Zongjian Qiu, Haili Geng, Yang Li, Rong Zhan, Zhihong Zheng

{"title":"Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation.","authors":"Yi Chen, Qinyun Cai, Zongjian Qiu, Haili Geng, Yang Li, Rong Zhan, Zhihong Zheng","doi":"10.1080/1120009X.2025.2540172","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2540172","url":null,"abstract":"This research aimed to assess the effectiveness of daratumumab in the treatment of relapsed and refractory multiple myeloma (RRMM) within a real - world setting. We conducted a retrospective analysis of the clinical features and treatment outcomes of patients diagnosed with RRMM at the Union Hospital of Fujian Medical University from 2018 to 2024. The study cohort consisted of 62 patients, with a median age of 62 years. 80.6% of patients received one line therapy before administration of daratumumab. The median follow - up duration was 16.1 (1.9 - 69.6) months, and the median number of daratumumab treatment cycles was 7.5 (1 - 72) courses. Among the 56 evaluable cases, the overall response rate (ORR) was 89.3%, which included 11 cases (19.6%) attaining a stringent complete response (sCR) and 13 cases (23.2%) achieving a complete response (CR). The median progression free survival (PFS) of the entire cohort was 25.2 months. The 1 - year and 3 - year PFS rates were 75.2% and 25.4% respectively. The median overall survival (OS) was 42.7 months. The 1 - year and 3 - year OS rates were 84.2% and 62.8% respectively. Multivariate analysis indicated that poor performance status was independent unfavorable prognostic factors for PFS and OS. In conclusions, an early daratumumab - based treatment regimen has demonstrated promising therapeutic potential for treating RRMM and warrants further validation and exploration in future clinical practice.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges. 单侧面神经麻痹后延长每周紫杉醇治疗：一个罕见的病例颅神经毒性与诊断挑战。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2025-07-28 DOI: 10.1080/1120009X.2025.2538945

Ergin Aydemir, Alper Türkel, Kübra Okur, Taylan Altıparmak, Mutlu Doğan

{"title":"Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges.","authors":"Ergin Aydemir, Alper Türkel, Kübra Okur, Taylan Altıparmak, Mutlu Doğan","doi":"10.1080/1120009X.2025.2538945","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2538945","url":null,"abstract":"Background: Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer. While peripheral neuropathy is a well-recognized dose-limiting toxicity of paclitaxel, cranial nerve involvement remains exceptionally rare. We report a case of unilateral facial nerve palsy in a breast cancer patient receiving standard-dose paclitaxel therapy, highlighting the diagnostic challenges in distinguishing drug-induced neurotoxicity from other aetiologies.Case report: A 43-year-old woman with metastatic breast cancer developed left facial nerve paralysis after 12 months of weekly paclitaxel treatment (80 mg/m2). Contrast-enhanced cranial Magnetic Resonance Imaging (MRI) demonstrated bilateral cranial nerve VII enhancement, creating diagnostic uncertainty between leptomeningeal metastasis, paclitaxel-induced neuritis, and idiopathic Bell's palsy. Paclitaxel was discontinued, and corticosteroid therapy was initiated. Clinical and radiological improvement at follow-up strongly supported a drug-related aetiology.Conclusion: This case illustrates the diagnostic complexity of facial nerve palsy in cancer patients receiving neurotoxic chemotherapy. The overlapping clinical and radiological features between drug-induced cranial neurotoxicity, leptomeningeal disease, and idiopathic causes present significant diagnostic challenges. Clinicians should maintain a high degree of suspicion for rare chemotherapy-related cranial neuropathies while pursuing comprehensive differential diagnosis, including infectious aetiologies and metastatic disease.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis. 卡莫来珠单抗联合经动脉化疗栓塞介入治疗肝癌合并肝硬化的临床评价

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-07-25 DOI: 10.1080/1120009X.2025.2535821

Jian Chen, Mengshan Huang

{"title":"Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis.","authors":"Jian Chen, Mengshan Huang","doi":"10.1080/1120009X.2025.2535821","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2535821","url":null,"abstract":"This retrospective study evaluated the clinical efficacy of camrelizumab combined with transarterial chemoembolization (TACE) in 120 hepatocellular carcinoma (HCC) patients with liver cirrhosis. Based on the intervention received, patients were categorized into an observation group (OG) (n = 60, underwent camrelizumab combined with TACE interventional therapy) and a control group (CG) (n = 60, underwent camrelizumab monotherapy). The OG showed significantly higher objective response (66.67% vs. 46.67%) and disease control rates (91.67% vs. 80.00%), improved immune function (elevated CD3+, CD4+, CD4+/CD8+), better liver function (reduced TB and ALT), and reduced tumor markers (AFP, CEA) compared to the CG. One-year follow-up revealed prolonged overall survival rate and progression-free survival, along with better quality-of-life scores in the OG. These findings suggest that camrelizumab combined with TACE demonstrates definitive short-term efficacy, improved immune and liver function, better survival outcomes, and favorable safety in HCC patients with liver cirrhosis, supporting its clinical value.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0